No Suppression on Wegovy: What This Really Means for Your Appetite

The myth: Wegovy should suppress your appetite from the very first pen

This is probably the most common misunderstanding about how semaglutide works. Many people start Wegovy expecting an obvious, near-immediate loss of interest in food. When the first few weeks feel unremarkable, they conclude the medicine is not working for them.

The reality is more gradual. The starting dose of 0.25 mg is a tolerability step, not a therapeutic one. Its job is to let your system adjust before the dose escalates. The clinical trials that showed around 15% average weight reduction over 68 weeks were run at the 2.4 mg maintenance dose, reached after roughly 16 weeks of titration. Expecting that effect at 0.25 mg is a bit like expecting a kettle to boil on a low simmer. Semaglutide's mechanism depends on the concentration of the drug in your system building over time, and the appetite signal from GLP-1 receptor activation in the hypothalamus is dose-sensitive. Lower doses mean a quieter signal.

The NHS medicines page for semaglutide describes appetite reduction as one of the expected effects, but it frames this as an effect that develops, not an instant switch. If you are still on a lower rung of the escalation ladder, the honest answer is: give it time, and keep talking to your prescriber.

When suppression really does seem absent, possible reasons worth knowing

Some people on the maintenance dose still report that hunger feels broadly normal. Several factors can genuinely reduce how much of the medicine reaches your system.

Storage is one that gets overlooked. Wegovy must be kept refrigerated at 2–8°C until use. If a pen has been left out for longer than the product information permits, or if it has been stored next to the freezer compartment in the fridge door and has partially frozen, the active ingredient can degrade. A pen that has been temperature-compromised may look identical to a normal one. Checking storage conditions is a practical first step, the Wegovy Patient Information Leaflet sets out the exact out-of-fridge window, and your prescriber or pharmacist can help you verify whether your storage has been correct.

Injection technique also matters. Subcutaneous injections that go into muscle rather than fat tissue, or that are administered into an area with a lot of scar tissue from repeated injections, can affect absorption. Rotating between the abdomen, thigh and upper arm reduces this risk.

There is also a biological dimension. GLP-1 receptor density and sensitivity varies between individuals; this is part of why GLP-1 receptor agonists produce different magnitudes of effect in different people, even at the same dose. Clinical trials report averages across thousands of participants; individual responses sit across a wide distribution.

When appetite suppression and mood feel connected

Some people notice that the effect on their relationship with food feels intertwined with their mood. This is not entirely surprising: the same GLP-1 receptors activated by semaglutide are present in brain regions involved in reward and emotional regulation. The relationship is still being studied, but it is clinically recognised.

A small number of people report low mood or emotional flatness while on Wegovy. Others, conversely, report that reduced food preoccupation has a positive effect on how they feel day to day. If you have noticed mood changes alongside a sense that your appetite suppression is inconsistent, it is worth raising both with your prescriber together rather than separately. There is useful context on whether Wegovy can cause depression, on whether those mood changes tend to resolve, and on whether Wegovy might have a positive effect on depression for some people that may be relevant to your situation.

Depression, anxiety and disordered eating can also affect the experience of appetite in complex ways that interact unpredictably with a medicine that alters satiety signals. Your prescriber is the right person to untangle this, not because the question is too difficult for you to ask, but because the answer genuinely depends on your individual history.

What to do if you genuinely feel no effect on the maintenance dose

If you have reached the 2.4 mg maintenance dose, your injection technique is consistent, storage has been correct, and you still notice no meaningful change in appetite or weight after several weeks, this is a conversation to have with your prescriber. It does not mean Wegovy is the wrong treatment, but it does mean the clinical picture needs reviewing. The NICE appraisal of semaglutide recommends that continuing treatment should be reviewed if less than 5% weight loss has occurred after six months on the maintenance dose. That is a formal review point, not a cutoff.

There may be practical adjustments that help. The higher 7.2 mg dose, approved by the MHRA in early 2026, provides another option for some patients. Whether that is appropriate for you is a clinical decision. Equally, the evidence and eligibility context for other weight-loss treatment options is worth knowing about.

If you are considering starting Wegovy for the first time and want that clinical conversation from the outset, our clinical team at nume reviews every consultation personally. You can also see detail on what Wegovy costs privately and what is included. When you are ready, start your free consultation and a GPhC-registered prescriber will review your information the same day.